Trial Profile
Baseline characteristics and the duration of transition period of Secukinumab treatment in moderate to severe Psoriasis.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Acronyms PROSPECT
- 13 Sep 2018 Results presented in a Novartis media release.
- 13 Sep 2018 According to a Novartis media release, from the study has been presented at the 27th European Academy of Dermatology and Venereology (EADV) Congress.
- 08 Jun 2017 New trial record